Sajesh Kalkandi Veettil

Sajesh Kalkandi Veettil

Auto-generated profile, based on publicly available information

Sajesh Kalkandi Veettil

Department of Pharmacy Practice, School of Pharmacy, IMU University, Kuala Lumpur, Malaysia

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 June 2022 in Journal of the American Pharmacists Association
Verified
Journal Article
Open access
LLLan My Le
Lan My Le
SVSajesh K. Veettil
Sajesh K. Veettil
DDDaniel Donaldson
Daniel Donaldson
WKWarittakorn Kategeaw
Warittakorn Kategeaw
RHRaymond Hutubessy
Raymond Hutubessy
NCNathorn Chaiyakunapruk
Nathorn Chaiyakunapruk
The underutilization of immunization services remains a big public health concern. Pharmacists can address this concern by playing an active role in immunization administration. We performed a systematic review and meta-analysis to assess the impact of pharmacist-involved interventions on immunization rates and other outcomes indirectly related to vaccine uptake. A systematic literature search was conducted using MEDLINE, Embase, and Cochrane Central Register of Controlled Trials databases from inception to February 2022 to identify randomized controlled trials (RCTs) and observational studies in which pharmacists were involved in the immunization process. Studies were excluded if no comparator was reported. Two reviewers independently completed data extraction and bias assessments using standardized forms. Meta-analyses were performed using a random-effects model. A total of 14 RCTs and 79 observational studies were included. Several types of immunizations were provided, including influenza, pneumococcal, herpes zoster, Tdap, and others in a variety of settings (community pharmacy, hospital, clinic, others). Pooled analyses from RCTs indicated that a pharmacist as immunizer (risk ratio 1.14 [95% CI 1.12–1.15]), advocator (1.31 [1.17–1.48]), or both (1.14 [1.12–1.15]) significantly increased immunization rates compared with usual care or non–pharmacist-involved interventions. The quality of evidence was assessed as moderate or low for those meta-analyses. Evidence from observational studies was consistent with the results found in the analysis of the RCTs. Pharmacist involvement as immunizer, advocator, or both roles has favorable effects on immunization uptake, especially with influenza vaccines in the United States and some high-income countries. As the practice of pharmacists in immunization has been expanded globally, further research on investigating the impact of pharmacist involvement in immunization in other countries, especially developing ones, is warranted.

16 September 2020 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
AFAlexander C. Ford
Alexander C. Ford
PMPaul Moayyedi
Paul Moayyedi
CBChristopher J. Black
Christopher J. Black
YYYuhong Yuan
Yuhong Yuan
SVSajesh K. Veettil
Sajesh K. Veettil
Yeong Yeh LeeYeong Yeh Lee
Yeong Yeh Lee

14 July 2020 in Cancers
Verified
Journal Article
Open access
PDF file
DGDivya Gopinath
Divya Gopinath
RMRohit Kunnath Menon
Rohit Kunnath Menon
SVSajesh K. Veettil
Sajesh K. Veettil
MBMichael Botelho
Michael Botelho
NJNewell Johnson
Newell Johnson
Whether “periodontal disease” can be considered as an independent risk factor for head and neck cancer (HNC) remains controversial. The aim of the current meta-analysis was to quantitatively assess this relationship in order to determine whether this represents a true risk factor, with implications for cancer prevention and management. PubMed, Scopus, and Embase databases were systematically searched. Selective studies were reviewed, and meta-analysis was performed to estimate the pooled odds ratio (OR) with 95% confidence intervals (CIs) on eligible studies using a random effects model. In total, 21 eligible observational studies (4 cohorts and 17 case-controls) were identified for qualitative synthesis after a review of 1051 articles. Significant heterogeneity could be identified in measures utilized for reporting of periodontal disease. Meta-analysis performed on nine studies that employed objective measures for reporting periodontal disease demonstrated a significant association between periodontal disease and HNC [OR 3.17, 95% CI, 1.78–5.64]. A diseased periodontium represents an independent risk marker, and a putative risk factor, for HNC. Prospective studies with standardized measures of periodontal disease severity and extent, integrated with microbiological and host susceptibility facets, are needed to elucidate the mechanisms of this positive association and whether treatment of the former influences the incidence and outcomes for HNC.

7 October 2021 in British Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
SVSajesh K. Veettil
Sajesh K. Veettil
SSSaranrat Sadoyu
Saranrat Sadoyu
EBElizabeth Mary Bald
Elizabeth Mary Bald
VCViji P. Chandran
Viji P. Chandran
SKScott Anh Tuan Khuu
Scott Anh Tuan Khuu
NCNathorn Chaiyakunapruk
Nathorn Chaiyakunapruk

16 May 2024 in Journal of Dentistry
Verified
Journal Article
Closed access
KGKoay Chun Giok
Koay Chun Giok
SVSajesh K. Veettil
Sajesh K. Veettil
RMRohit Kunnath Menon
Rohit Kunnath Menon

3 September 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
TWTse Yee Wong
Tse Yee Wong
YLYee Shen Loo
Yee Shen Loo
SVSajesh Kalkandi Veettil
Sajesh Kalkandi Veettil
PWPei Se Wong
Pei Se Wong
GDGopinath Divya
Gopinath Divya
RMRohit Kunnath Menon
Rohit Kunnath Menon
Invasive fungal infections are a potentially life-threatening complication in immunocompromised patients. The aim of this study was to assess the efficacy and safety of posaconazole as compared with other antifungal agents for preventing invasive fungal infections in immunocompromised patients. Embase, CENTRAL, and MEDLINE were searched for randomized conweekmonthtrolled trials (RCTs) up to June 2020. A systematic review with meta-analysis of RCTs was performed using random-effects model. Trial sequential analysis (TSA) was conducted for the primary outcome to assess random errors. A total of five RCTs with 1,617 participants were included. Posaconazole prophylaxis was associated with a significantly lower risk of IFIs (RR, 0.43 [95% CI 0.28 to 0.66, p = 0.0001]) as compared to other antifungal agents. No heterogeneity was identified between studies (I2 = 0%). No significant associations were observed for the secondary outcomes measured, including risk reduction of invasive aspergillosis and candidiasis, clinical failure, all-cause mortality, and treatment-related adverse events, except for infection-related mortality (RR, 0.31 [95% CI 0.15 to 0.64, p = 0.0001]). Subgroup analysis favoured posaconazole over fluconazole for the prevention of IFIs (RR, 0.44 [95% CI 0.28 to 0.70, p = 0.0004]). TSA confirmed the prophylactic benefit of posaconazole against IFIs. Posaconazole is effective in preventing IFIs among immunocompromised patients, particularly those with hematologic malignancies and recipients of allogenic hematopoietic stem cell transplantation.